ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 680

Variability over Time in Patient-Reported Outcome Measures in Patients with Ankylosing Spondylitis

Ivette Essers1,2, Matthias Busch2, Annelies Boonen1,3, Sofia Ramiro4, Désirée van der Heijde5, Robert B.M. Landewé6,7 and Astrid van Tubergen1,2, 1School for Public Health and Primary Care (CAPHRI), Maastricht University, Maastricht, Netherlands, 2Rheumatology, Maastricht University Medical Center, Maastricht, Netherlands, 3Maastricht University Medical Center, Maastricht, Netherlands, 4Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 5Department of Rheumatology, Leiden University Medical Center, Leiden, the Netherlands, Leiden, Netherlands, 6Rheumatology, Atrium Medical Center, Heerlen, Netherlands, 7Department of Rheumatology, Amsterdam Rheumatology Center, Amsterdam, Netherlands

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: Ankylosing spondylitis (AS) and outcome measures

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 8, 2015

Title: Spondylarthropathies and Psoriatic Arthritis - Clinical Aspects and Treatment Poster I: Clinical Aspects and Assessments

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: The BASDAI, BAS-G, and a VAS for spinal
pain (VAS-pain) are used to assess disease outcomes in AS. The intervals with
which these patient-reported outcome measures (PROMs) are assessed vary widely,
depending on the purpose of the assessment, and as such variability in outcome
may occur. However, it is currently unknown what the extent and relevance of this
variability is, and what the consequences of applying increasing intervals are on
follow-up of individual patients. The aim of the study was to evaluate in AS 1)
the variability of self-reported disease activity, patient global and spinal
pain during 2 years of follow up, 2) the clinical relevance of this variability
on a patient level, and 3) the effect of increasing intervals between two measurements
on this variability on a measurement level.

Methods: Dutch patients from the Outcome in AS International
Study (OASIS) completed the BASDAI, BAS-G, and VAS-pain every 2 months during 2
years. Mixed linear models were used to analyze time trends in the average
scores over time. The minimal clinically important difference (MCID) was used
to detect relevant changes (worsening or improvement) between two measurements. On a patient level, the frequency of exceeding the MCID, using
intervals of 2 months, was calculated. Next, the intervals between two measurements (from 2- to 24-months) were
increased to investigate the variability using all available measurements from
individual patients.

Results: 90 patients (mean age 47.3 (SD 11.4) years, 68% male, mean symptom duration 25.2 (SD
11.3) years) completed the PROMs. The mean of each measure was stable over time. On the patient level,
however, large variability was found. Using 2-months intervals, the average frequency of exceeding the MCID (in either direction) was 4.7 (SD 2.5) times for the BASDAI, 3.3
(SD 2.3) for the BAS-G, and 2.8 (SD 2.0) for the VAS-pain in the 2-year period
(from a maximum of 12). On an
observational level, exceeding
of the MCID was frequently seen in all intervals. This markedly increased with
prolongation of the interval in observations showing worsening over time (Table
1).

Conclusion: Substantial variability in the BASDAI,
BAS-G, and VAS-pain was found in individuals over time. Clinically relevant
changes were frequently observed, especially in observations with worsening
more frequently relevant changes occurred with prolongation of the intervals.
This intermediate information between two measurements, which may be clinically
important, might be missed when intervals are prolonged. 

 

 


Disclosure: I. Essers, None; M. Busch, None; A. Boonen, None; S. Ramiro, None; D. van der Heijde, AbbVie, 5,Amgen, 5,Astellas, 5,AstraZeneca, 5,Bristol-Myers Squibb, 5,Celgene, 5,Daiichi Pharmaceutical Corporation, 5,Eli Lilly and Company, 5,Galapagos, 5,Merck Pharmaceuticals, 5,Novartis Pharmaceutical Corporation, 5,Pfizer Inc, 5,Roche Pharmaceuticals, 5,UCB Pharma, 5; R. B. M. Landewé, None; A. van Tubergen, None.

To cite this abstract in AMA style:

Essers I, Busch M, Boonen A, Ramiro S, van der Heijde D, Landewé RBM, van Tubergen A. Variability over Time in Patient-Reported Outcome Measures in Patients with Ankylosing Spondylitis [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/variability-over-time-in-patient-reported-outcome-measures-in-patients-with-ankylosing-spondylitis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/variability-over-time-in-patient-reported-outcome-measures-in-patients-with-ankylosing-spondylitis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology